Hosted by ApoE4 Alzheimer's Alliance & ApoE4.Info
Wednesday, August 19, 2026 | 3:00 PM ET
Wednesday, August 19, 2026
3:00 PM Eastern Time (USA)
Approximately 60 minutes including Q&A session
Zoom Webinar
Join us to explore obicetrapib's regulatory pathway and its potential future for APOE4 carriers. NewAmsterdam Pharma's investigational once-daily oral drug has shown significant reduction in p-tau217 levels, a key Alzheimer's biomarker, suggesting potential to impact both cholesterol and Alzheimer's disease progression.
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing lipid-lowering treatments for cardiovascular disease. Their investigational drug Obicetrapib has demonstrated meaningful reductions in plasma p-tau217 levels in patients with atherosclerotic cardiovascular disease, including ApoE4 carriers — suggesting dual potential for cardiovascular and Alzheimer's benefits.
A better tomorrow through innovation.
Join us for this live webinar featuring NewAmsterdam Pharma's obicetrapib and its potential for the APOE4 community. Free and open to all.
Register Now on ZoomYou will be redirected to Zoom to complete your registration